ArticleBMC psychiatry2026
Value drivers and barriers to the adoption of Precision Psychiatry in Latin America: a qualitative study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreating major depressive disorder is difficult due to the lack of objective criteria to guide therapy. Decision making often relies on trial and error, which limits treatment effectiveness. Precision psychiatry has been presented as a new approach that uses biological and multimodal data to support diagnosis and treatment, similar to precision medicine in other fields.
aimsThis study aims to explore the perceptions of key experts regarding the drivers and barriers to the adoption of precision psychiatry in Latin America. Secondary objectives are to explore the conceptualization of precision psychiatry, explore its potential benefits in the context of MDD, identify potential drivers and barriers to its implementation in the region, and identify context specific considerations for future implementation.
methodsThis is a qualitative study based on interviews, and a hybrid deductive-inductive content analysis was applied. A scoping review informed the development of a semi structured interview guide. Semi structured interviews were then conducted with experts involved in healthcare provision, mental health policy shaping, and academic research. The interviews explored the perceived value of precision psychiatry, its potential contribution to the treatment of major depressive disorder, and the challenges surrounding its adoption in the region.
resultsParticipants viewed precision psychiatry as a promising approach to improve diagnostic accuracy, guide targeted treatment, and use healthcare resources more efficiently. These advantages were seen as particularly relevant for major depressive disorder due to its high burden, heterogeneity, and prevalence of treatment resistant cases in Latin America. Key barriers included limited understanding of precision concepts, insufficient evidence on effectiveness and cost, low provider awareness, high implementation costs, regulatory constraints, and systemic challenges such as under-resourced services, stigma, and shortages of trained professionals.
conclusionPrecision psychiatry has the potential to improve mental health care in Latin America according to participants, especially for major depressive disorder. Realizing this potential will require stronger evidence, greater investment in research and training, improved information systems, stronger mental health policies, and regulatory processes that can assess clinical, economic, and societal value. Coordinated efforts across stakeholders are necessary to support its development and adoption. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.